4-1BB immunotherapy: advances and hurdles

참고문헌 (107)

1. Kwon, B. S., "Isolation and initial characterization of multiple species of T-lymphocyte subset cDNA clones", Proc. Natl Acad. Sci. USA, 84, pp.2896~2900 (1987)
2. Kwon, B. S., "cDNA sequences of two inducible T-cell genes", Proc. Natl Acad. Sci. USA, 86, pp.1963~1967 (1989)
3. Zhou, Z., "Characterization of human homologue of 4-1BB and its ligand", Immunol. Lett, 45, pp.67~73 (1995)
4. Croft, M., "Co-stimulatory members of the TNFR family: keys to effective T-cell immunity?", Nat. Rev. Immunol, 3, pp.609~620 (2003)
5. Vinay, D. S., "Role of 4-1BB in immune responses", Semin. Immunol, 10, pp.481~489 (1998)
6. Futagawa, T., "Expression and function of 4-1BB and 4-1BB ligand on murine dendritic cells", Int. Immunol, 14, pp.275~286 (2002)
7. Arch, R. H., "4-1BB and Ox40 are members of a tumor necrosis factor(TNF)-nerve growth factor receptor subfamily that bind TNF receptor associated factors and activate nuclear factor kappaB", Mol. Cell Biol, 18, pp.558~565 (1998)
8. Jang, I. K., "Human 4-1BB(CD137)signals are mediated by TRAF2 and activate nuclear factor-kappa B", Biochem. Biophys. Res. Commun, 242, pp.613~620 (1998)
9. Hurtado, J. C., "Signals through 4-1BB are costimulatory to previously activated splenic T cells and inhibit activation-induced cell death", J. Immunol, 158, pp.2600~2609 (1997)
10. Lee, H. W., "4-1BB promotes the survival of CD8+ T lymphocytes by increasing expression of Bcl-xL and Bfl-1", J. Immunol, 169, pp.4882~4888 (2002)
11. Sabbagh, L., "ERK-dependent Bim modulation downstream of the 4-1BB TRAF1 signaling axis is a critical mediator of CD8 T cell survival in vivo", J. Immunol, 180, pp.8093~8101 (2008)
12. Kim, Y. J., "Human 4-1BB regulates CD28 co-stimulation to promote Th1 cell responses", Eur. J. Immunol, 28, pp.881~890 (1998)
13. Oh, H. S., "4-1BB signaling enhances primary and secondary population expansion of CD8+ T cells by maximizing autocrine IL-2", IL-2 receptor signaling, 2015, pp.10, e0126765~
14. Kim, Y. J., "Novel T cell antigen 4-1BB associates with the protein tyrosine kinase p56lck1", J. Immunol, 151, pp.1255~1262 (1993)
15. Glez-Vaz, J., "CD137 (4-1BB) requires physically associated cIAPs for signal transduction and antitumor effects", Sci. Adv, 9, pp.eadf6692~ (2023)
16. Shu, H. -B., "The tumor necrosis factor receptor 2 signal transducers TRAF2 and c-IAP1 are components of the tumor necrosis factor receptor 1 signaling complex", Proc. Natl Acad. Sci. USA, 93, pp.13973~13978 (1996)
17. Goodwin, R. G., "Molecular cloning of a ligand for the inducible T cell gene 4-1BB : a member of an emerging family of cytokines with homology to tumor necrosis factor", Eur. J. Immunol, 23, pp.2631~2641 (1993)
18. Choi, B. K., "The murine CD137", CD137 ligand signalosome : a signal platform generating signal complexity, 2020, pp.11, 553715~
19. Heng, T. S., "The Immunological Genome Project : networks of gene expression in immune cells", Nat. Immunol, 9, pp.1091~1094 (2008)
20. Karlsson, M., "A single–cell type transcriptomics map of human tissues", Sci. Adv, 7, pp.eabh2169~ (2021)
21. Salih, H. R., "Constitutive expression of functional 4-1BB(CD137)ligand on carcinoma cells", J. Immunol, 165, pp.2903~2910 (2000)
22. Grimmig, T., "Expression of Tumor-mediated CD137 ligand in human colon cancer indicates dual signaling effects", Oncoimmunology, 8, pp.e1651622~ (2019)
23. Vanamee, É. S., "Structural principles of tumor necrosis factor superfamily signaling", Sci. Signal, 11, pp.eaao4910~ (2018)
24. Bitra, A., "Crystal structures of the human 4-1BB receptor bound to its ligand 4-1BBL reveal covalent receptor dimerization as a potential signaling amplifier", J. Biol. Chem, 293, pp.9958~9969 (2018)
25. Bitra, A., "Crystal structure of the m4-1BB", 4-1BBL complex reveals an unu sual dimeric ligand that undergoes structural changes upon 4-1BB receptor binding, 2019, pp.294, 1831~1845
26. Bitra, A., "Crystal structure of murine 4-1BB and its interaction with 4-1BBL support a role for galectin-9 in 4-1BB signaling", J. Biol. Chem, 293, pp.1317~1329 (2018)
27. "Crystal Structure Of 4-1bbl/4-1bb Complex In C2 Space Group" (2018)[URL]
28. "Crystal Structure Of Murine 4-1BB/4-1BBL Complex" (2018)[URL]
29. Madireddi, S., "Galectin-9 controls the therapeutic activity of 4-1BB-targeting antibodies", J. Exp. Med, 211, pp.1433~1448 (2014)
30. Nielsen, M. A., "Galectin-3 decreases 4-1BBL bioactivity by crosslinking soluble and membrane expressed 4-1BB", Front. Immunol, 13, pp.915890~ (2022)
31. Buck, M. D., "T cell metabolism drives immunity", J. Exp. Med, 212, pp.1345~1360 (2015)
32. Teijeira, A., "Mitochondrial morphological and functional reprogramming following CD137(4-1BB)costimulation", Cancer Immunol. Res, 6, pp.798~811 (2018)
33. Kawalekar, O. U., "Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells", Immunity, 44, pp.380~390 (2016)
34. Menk, A. V., "4-1BB costimulation induces T cell mitochondrial function and biogenesis enabling cancer immunotherapeutic responses", J. Exp. Med, 215, pp.1091~1100 (2018)
35. Choi, B. K., "4-1BB signaling activates glucose and fatty acid metabolism to enhance CD8(+)T cell proliferation", Cell. Mol. Immunol, 14, pp.748~757 (2017)
36. Rafiq, S., "Engineering strategies to overcome the current roadblocks in CAR T cell therapy", Nat. Rev. Clin. Oncol, 17, pp.147~167 (2020)
39. Brentjens, R. J., "CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia", Sci. Transl. Med, 5, pp.177ra38~ (2013)
40. Maude, S. L., "Chimeric antigen receptor T cells for sustained remissions in leukemia", N. Engl. J. Med, 371, pp.1507~1517 (2014)
41. Long, A. H., "4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors", Nat. Med, 21, pp.581~590 (2015)
42. Zhao, Z., "Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells", Cancer Cell, 28, pp.415~428 (2015)
43. Sun, C., "THEMIS-SHP1 recruitment by 4-1BB tunes LCK-mediated priming of chimeric antigen receptor-redirected T cells", Cancer Cell, 37, pp.216~225 (2020)
44. Roselli, E., "4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells", J. Immun other. Cancer, 9, pp.e003354~ (2021)
45. Pollok, K. E., "4-1BB T-cell antigen binds to mature B cells and macrophages, and costimulates anti-mu-primed splenic B cells", Eur. J. Immunol, 24, pp.367~374 (1994)
46. DeBenedette, M. A., "Analysis of 4-1BB ligand(4-1BBL)-deficient mice and of mice lacking both 4-1BBL and CD28 reveals a role for 4-1BBL in skin allograft rejection and in the cytotoxic T cell response to influenza virus", J. Immunol, 163, pp.4833~4841 (1999)
47. Cannons, J. L., "4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy", J. Immunol, 167, pp.1313~1324 (2001)
48. Cho, E., "4-1BB-4-1BBL cis-interaction contributes to the survival of self reactive CD8(+) T cell", Cell. Mol. Immunol (2023)[DOI]
49. Eun, S. Y., "4-1BB ligand signaling to T cells limits T cell activation", J. Immunol, 194, pp.134~141 (2015)
50. Kwon, B. S., "Immune responses in 4-1BB(CD137)-deficient mice", J. Immunol, 168, pp.5483~5490 (2002)
51. Lin, G. H., "Endogenous 4-1BB ligand plays a critical role in protection from influenza-induced disease", J. Immunol, 182, pp.934~947 (2009)
52. Bertram, E. M., "A switch in costimulation from CD28 to 4-1BB during primary versus secondary CD8 T cell response to influenza in vivo", J. Immunol, 172, pp.981~988 (2004)
53. Tan, J. T., "4-1BB ligand, a member of the TNF family, is important for the generation of antiviral CD8 T cell responses", J. Immunol, 163, pp.4859~4868 (1999)
54. Tan, J. T., "4-1BB costimulation is required for protective anti-viral immunity after peptide vaccination", J. Immunol, 164, pp.2320~2325 (2000)
55. Fuse, S., "CD8+ T cell dysfunction and increase in murine gamma herpesvirus latent viral burden in the absence of 4-1BB ligand", J. Immunol, 178, pp.5227~5236 (2007)
56. Rodriguez, R., "Concomitant PIK3CD and TNFRSF9 deficiencies cause chronic active Epstein-Barr virus infection of T cells", J. Exp. Med, 216, pp.2800~2818 (2019)
57. Somekh, I., "CD137 deficiency causes immune dysregulation with predis position to lymphomagenesis", Blood, 134, pp.1510~1516 (2019)
58. Alosaimi, M. F., "Immunodeficiency and EBV-induced lymphoproliferation caused by 4-1BB deficiency", J. Allergy Clin. Immunol, 144, pp.574~583 (2019)
59. Vinay, D. S., "Absence of 4 1BB gene function exacerbates lacrimal gland inflammation in autoimmune-prone MRL-Faslpr mice", Invest. Ophthalmol. Vis. Sci, 48, pp.4608~4615 (2007)
60. Vinay, D. S., "Role of endogenous 4-1BB in the development of systemic lupus erythematosus", Immunology, 122, pp.394~400 (2007)
61. Lee, S. W., "Functional dichotomy between OX40 and 4-1BB in modulating effector CD8 T cell responses", J. Immunol, 177, pp.4464~4472 (2006)
62. Lee, S. W., "Enhanced CD4 T cell responsiveness in the absence of 4-1BB", J. Immunol, 174, pp.6803~6808 (2005)
63. Choi, B. K., "Peripheral 4-1BB signaling negatively regulates NK cell devel opment through IFN-gamma", J. Immunol, 185, pp.1404~1411 (2010)
64. Humphreys, I. R., "Biphasic role of 4-1BB in the regulation of mouse cytomegalovirus-specific CD8(+)T cells", Eur. J. Immunol, 40, pp.2762~2768 (2010)
65. Dawicki, W., "Expression and function of 4-1BB during CD4 versus CD8 T cell responses in vivo", Eur. J. Immunol, 34, pp.743~751 (2004)
66. Korman, A. J., "The foundations of immune checkpoint blockade and the ipilimumab approval decennial", Nat. Rev. Drug Discov, 21, pp.509~528 (2022)
67. Qin, S., "Novel immune checkpoint targets : moving beyond PD-1 and CTLA 4", Mol. Cancer, 18, pp.155~ (2019)
68. Melero, I., "Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors", Nat. Med, 3, pp.682~685 (1997)
69. Yeonjoo, C., "T-cell agonists in cancer immunotherapy", J. Immunother. Cancer, 8, pp.e000966~ (2020)
70. Claus, C., "The emerging landscape of novel 4-1BB(CD137)agonistic drugs for cancer immunotherapy", MAbs, 15, pp.2167189~ (2023)
71. Sanmamed, M. F., "Twists and turns to translating 4-1BB cancer immu notherapy", Sci. Transl. Med, 11, pp.eaax4738~ (2019)
72. Sznol, M., "Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients(pts)with advanced cancer(CA)", J. Clin. Oncol, 26, pp.3007~3007 (2008)
73. Segal, N. H., "Results from an integrated safety analysis of urelumab, an agonist anti-CD137 monoclonal antibody", Clin. Cancer Res, 23, pp.1929~1936 (2017)
74. Tolcher, A. W., "Phase Ib study of utomilumab(PF-05082566), a 4-1BB", CD137agonist, in combination with pembrolizumab(MK-3475)in patients with advanced solid tumors, 2017, pp.23, 5349~5357
75. Chin, S. M., "Structure of the 4-1BB", 4-1BBL complex and distinct binding and functional properties of utomilumab and urelumab, 2018, pp.9, 4679~
76. "Structure Of The Human 4-1BB/Utomilumab Fab Complex" (2018)[URL]
77. "Structure Of The Human 4-1BB / Urelumab Fab Complex" (2018)[URL]
78. Li, Y., "Limited cross-linking of 4-1BB by 4-1BB ligand and the agonist monoclonal antibody utomilumab", Cell Rep, 25, pp.909~920 (2018)
79. Qi, X., "Optimization of 4-1BB antibody for cancer immunotherapy by bal ancing agonistic strength with FcγRaffinity", Nat. Commun, 10, pp.2141~ (2019)
80. Yu, X., "Reducing affinity as a strategy to boost immunomodulatory anti body agonism", Nature, 614, pp.539~547 (2023)
81. Chodorge, M., "A series of Fas receptor agonist antibodies that demonstrate an inverse correlation between affinity and potency", Cell Death Differ, 19, pp.1187~1195 (2012)
82. Claire, G., "377 AGEN2373 is a CD137 agonist antibody designed to leverage optimal CD137 and FcγR co-targeting to promote antitumor immunologic effects", J. Immunother. Cancer, 8, pp.A229~ (2020)
83. Liu, G., "Targeting CD137(4-1BB)towards improved safety and efficacy for cancer immunotherapy", Front. Immunol, 14, pp.1208788~ (2023)
84. Gao, Y., "Development and characterization of a novel human CD137agonistic antibody with anti-tumor activity and a good safety profile in non human primates", FEBS Open Biol, 12, pp.2166~2178 (2022)
85. Eskiocak, U., "Differentiated agonistic antibody targeting CD137 eradicates large tumors without hepatotoxicity", JCI Insight, 5, pp.e133647~ (2020)
86. Ana, C., "714 ATOR-1017, a 4–1BB antibody, demonstrates promising safety and proof of mechanism in a first-in-human study in patients with advanced solid malignancies", J. Immunother. Cancer, 10, pp.A747~ (2022)
87. Kamata-Sakurai, M., "Antibody to CD137 activated by extracellular adeno sine triphosphate is tumor selective and broadly effective in vivo without sys temic immune activation", Cancer Discov, 11, pp.158~175 (2021)
88. Ciombor, K. K., "Aflibercept", Clin. Cancer Res, 19, pp.1920~1925 (2013)
89. Jen, E. Y., "FDA approval : blinatumomab for patients with b-cell precursor acute lymphoblastic leukemia in morphologic remission with minimal residual disease", Clin. Cancer Res, 25, pp.473~477 (2019)
90. Geuijen, C., "A human CD137×PD-L1 bispecific antibody promotes anti tumor immunity via context-dependent T cell costimulation and checkpoint blockade", Nat. Commun, 12, pp.4445~ (2021)
91. Muik, A., "Preclinical characterization and phase I trial results of a bispecific antibody targeting PD-L1 and 4-1BB(GEN1046)in patients with advanced refractory solid tumors", Cancer Discov, 12, pp.1248~1265 (2022)
92. Muik, A., "DuoBody-CD40x4-1BB induces dendritic-cell maturation and enhances T-cell activation through conditional CD40 and 4-1BB agonist activity", J. Immunother. Cancer, 10, pp.e004322~ (2022)
93. You, G., "B7-H3×4-1BB bispecific antibody augments antitumor immunity by enhancing terminally differentiated CD8(+) tumor-infiltrating lymphocytes", Sci. Adv, 7, pp.eaax3160~ (2021)
94. Claus, C., "Tumor-targeted 4-1BB agonists for combination with T cell bis pecific antibodies as off-the-shelf therapy", Sci. Transl. Med, 11, pp.eaav5989~ (2019)
95. Melero, I., "A first-in-human study of the fibroblast activation protein-tar geted, 4-1BB agonist RO7122290 in patients with advanced solid tumors", Sci. Transl. Med, 15, pp.eabp9229~ (2023)
96. Shuford, W. W., "4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses", J. Exp. Med, 186, pp.47~55 (1997)
97. Kim, S. H., "Chronic activation of 4-1BB signaling induces granuloma development in tumor-draining lymph nodes that is detrimental to subsequent CD8+ T cell responses", Cell. Mol. Immunol, 18, pp.1956~1968 (2021)
98. Chiba, K., "FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphin gosine 1-phosphate receptors", Pharmacol. Ther, 108, pp.308~319 (2005)
99. Fransen, M. F., "Tumor-draining lymph nodes are pivotal in PD-1", PD-L1checkpoint therapy, 2018, pp.3, e124507~
100. Dammeijer, F., "The PD-1", PD-L1-checkpoint restrains T cell immunity in tumor-draining lymph nodes, 2020, pp.38, 685~700
101. Miller, R. E., "4-1BB-specific monoclonal antibody promotes the generation of tumor-specific immune responses by direct activation of CD8 T cells in a CD40-dependent manner", J. Immunol, 169, pp.1792~1800 (2002)
102. Gray, J. C., "Optimising anti-tumour CD8 T-cell responses using combina tions of immunomodulatory antibodies", Eur. J. Immunol, 38, pp.2499~2511 (2008)
103. Tseng, D., "Anti-CD47 antibody–mediated phagocytosis of cancer by mac rophages primes an effective antitumor T-cell response", Proc. Natl Acad. Sci. USA, 110, pp.11103~11108 (2013)
104. Gauttier, V., "Selective SIRPα blockade reverses tumor T cell exclusion and overcomes cancer immunotherapy resistance", J. Clin. Invest, 130, pp.6109~6123 (2020)
105. Logtenberg, M. E. W., "The CD47-SIRPαimmune checkpoint", Immunity, 52, pp.742~752 (2002)
106. Kwon, B. S., "466 Combination therapy with anti-VSIG4 and anti-PD-L1 suppress growth of tumor via conditioning of tumor microenviron ment", J. Immunother. Cancer, 10, pp.A486~A486 (2022)
107. Sazinsky, S., "Abstract 5613 : targeting VSIG4, a novel macrophage check point, repolarizes suppressive macrophages which induces an inflammatory response in primary cell in vitro assays and fresh human tumor cultures, and inhibits tumor growth in in vivo murine tumor models", Cancer Res, 82, pp.5613~5613 (2022)